



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/645,756	08/20/2003	John E. Monahan	MRI-062	8064
959 7590 08/22/2007 LAHIVE & COCKFIELD, LLP ONE POST OFFICE SQUARE BOSTON, MA 02109-2127			EXAMINER RAWLINGS, STEPHEN L	
			ART UNIT 1643	PAPER NUMBER
			MAIL DATE 08/22/2007	DELIVERY MODE PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Examiner-Initiated Interview Summary	Application No.	Applicant(s)	
	10/645,756	MONAHAN ET AL.	
	Examiner	Art Unit	
	Stephen L. Rawlings, Ph.D.	1643	

All Participants:

(1) Stephen L. Rawlings, Ph.D.

(2) Maria Laccotripe Zacharakis, Ph.D., J.D.

Date of Interview: 2 August 2007

Type of Interview:

☒ Telephonic

☐ Video Conference

☐ Personal (Copy given to: ☐ Applicant ☐ Applicant's representative)

Exhibit Shown or Demonstrated: ☐ Yes ☐ No

If Yes, provide a brief description:

Status of Application: _____

(3) Marcie Clark.

(4) _____

Time: _____

Part I.

Rejection(s) discussed:

ODP over copending Application No. 11/510,530, which is a continuation of Application No. 10/171,311, filed June 12, 2002

Claims discussed:

1, 5-9, 11-21, and 50-56

Prior art documents discussed:

N/A

Part II.


SUBSTANCE OF INTERVIEW DESCRIBING THE GENERAL NATURE OF WHAT WAS DISCUSSED:

See Continuation Sheet

Part III.

☐ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview directly resulted in the allowance of the application. The examiner will provide a written summary of the substance of the interview in the Notice of Allowability.

☒ It is not necessary for applicant to provide a separate record of the substance of the interview, since the interview did not result in resolution of all issues. A brief summary by the examiner appears in Part II above.


STEPHEN L. RAWLINGS, PH.D.
PRIMARY EXAMINER

(Examiner/SPE Signature)

(Applicant/Applicant's Representative Signature – if appropriate)

Continuation of Substance of Interview including description of the general nature of what was discussed: The Examiner telephoned Applicant's representatives to propose entry of an Examiner's amendment, which would place this application in condition for allowance, provided that Applicant file a terminal disclaimer or otherwise obviate the issue of ODP. More particularly, the Examiner proposed that claim 9 be amended to recite, "consisting of an antibody and an antigen binding fragment thereof"; claim 18 be amended to recite, "is a further indication that the patient"; claim 19 be amended to recite, "the level of expression of each of said plurality of markers", and "is a further indication that the patient"; claims 51 and 52 be cancelled; claims 53 and 54 be amended to depend from claims 49 and 50, respectively; claim 53 be further amended to recite, "in the cervical adenocarcinoma differs from", striking "cell"; claim 54 be further amended to recite, "in the cervical squamous cell carcinoma differs from", adding "carcinoma"; and claim 55 be canceled. Furthermore, the Examiner indicated that claims 11-15, drawn to the invention of Group II, wherein said marker is M666, would be rejoined with claims directed to the elected invention, and to that extent, the restriction and election requirement would then be withdrawn. The Examiner further indicated that claim 15 should then be amended to explicitly recite the specific stringent hybridization conditions to which the claim refers by incorporation of the descriptive language set forth in the specification in the last sentence of paragraph [0153] of the published application. Applicant's representatives decided that Applicant would file this amendment, so that they would have more time to determine the best and most appropriate course of action to obviate the issue of ODP over claim 4 of the copending application.



STEPHEN L. RAWLINGS, PH.D.
PRIMARY EXAMINER